Drug intelligence / Profile preview

Ziying Granules

Development stage: Phase 2
Lead developer: Fangsheng Pharmaceutical
Administration: Oral

Overview

Ziying Granules (紫英颗粒) is an investigational Traditional Chinese Medicine (TCM) developed by Hunan Fangsheng Pharmaceutical for the treatment of gynecological conditions, specifically chronic pelvic inflammatory disease (CPID) and its sequelae. The drug is formulated as oral granules and is designed to alleviate symptoms such as chronic pelvic pain and inflammation associated with pelvic inflammatory disease. It has been evaluated in Phase 3 clinical trials in China, positioning it as a late-stage candidate in the developer's gynecological pipeline. As a TCM product, it likely utilizes a multi-component approach to address the complex pathophysiology of chronic inflammation in the female reproductive system.

Other names: 紫英颗粒Ziying Keli

Beyond the preview

Go deeper on Ziying Granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ziying Granules.

Explore the full profile